OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Newron Pharmaceuticals S.p.A./  IT0004147952  /

Quotrix
2024-05-31  12:53:46 PM Chg. +0.4500 Volume Bid5:30:21 PM Ask5:30:21 PM Market Capitalization Dividend Y. P/E Ratio
10.0800EUR +4.67% 500
Turnover: 5,040		 10.1600Bid Size: 160 10.3400Ask Size: 160 181.76 mill.EUR - -
GlobeNewswire 2021-05-05 Supernus Announces Paragraph IV ANDA Filing for XADAGO®
GlobeNewswire 2020-12-16 Kymera Therapeutics Announces Key Leadership Appointments
GlobeNewswire 2018-09-25 Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2025 - Focus on Marketed, Clin...
GlobeNewswire 2018-06-22 Global CNS Therapeutics Markets, 2016-2018 & 2024: Patent Expiries of Major Drugs Exert Downward Pre...
GlobeNewswire 2018-02-06 CNS Therapeutics - Global Strategic Business Report 2017 - Burgeoning Global Aging Populace, Longer ...
GlobeNewswire 2018-01-16 Parkinson's Disease Drugs Market, 2022: Levodopa Therapy, Dopamine Therapy, MAO-B Inhibitor Therapy,...
GlobeNewswire 2018-01-08 ABLYNX ANNOUNCES BOARD CHANGES
GlobeNewswire 2018-01-08 ABLYNX ANNOUNCES BOARD CHANGES
GlobeNewswire 2017-12-22 Saniona AB: Notice of extraordinary shareholders' meeting in Saniona AB
GlobeNewswire 2017-12-22 Saniona AB: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the B...
GlobeNewswire 2013-10-07 ABLYNX ANNOUNCES INTENTION TO APPOINT THREE NEW DIRECTORS AND ELECT A NEW CHAIRMAN OF ITS BOARD
GlobeNewswire 2012-02-24 Biotie Therapies Corp. financial statement release 1 January - 31 December 2011
GlobeNewswire 2011-11-04 Biotie Therapies Corp. Interim report 1 January - 30 September 2011
GlobeNewswire 2011-10-28 Biotie Terminates the Agreement to Acquire Newron
GlobeNewswire 2011-10-21 Biotie informed that Merck Serono is returning full global rights for safinamide to Newron
GlobeNewswire 2011-10-05 Notice to Biotie shareholders on registration of merger plan and documents available for review
GlobeNewswire 2011-09-27 Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Ne...
GlobeNewswire 2011-02-02 Statement
GlobeNewswire 2011-01-25 Santhera Statement